The Clinical Trials Office (CTO) provides clinical, regulatory and administrative research services for more than 60 principal investigators. At any one time, the CTO manages approximately 475 trials - 200 active enrolling trials, 200 closed-to-accrual trials with patients in follow-up and 75 pending trials in the approval process.
The CTO participates in phase I, II and III clinical trials originating from the NCI’s National Clinical Trials Network, selected pharmaceutical-sponsored and investigator-initiated studies. We have capabilities for conducting phase I trials and managing multicenter studies. The CTO has demonstrated success in clinical trial management with Institutional Review Board approval averaging less than 100 days. Our annual rate of interventional clinical trial enrollment is more than 10% with 26 percent of those enrolled representing minority populations.
In 2014 MUSC was awarded one of only twelve Minority-Underserved NCI Community Oncology Research Program (NCORP) grants in the country. The goal of NCORP is to bring cancer clinical trials to individuals in their own communities. Given MUSC’s patient population is more than 30% minority and/or underserved, MUSC was awarded a minority-underserved NCORP. The aim of MU-NCORP is to facilitate minority and underserved participation in clinical research, integrate disparities research questions across all study types and settings and accelerate knowledge transfer into clinical practice and health systems and organization.
The Clinical Trials Office provides centralized IRB and quality assurance services to five community cancer centers serving rural and minority communities throughout South Carolina. By partnering with over 20 community oncologists, MUSC is able to increase patient access to cancer clinical trials within communities across the state.
Hollings investigators have long participated in phase I clinical trials. Under the direction of Carolyn Britten, M.D., the Phase I program has supported numerous phase I trials spanning from first-in-man, first-in-class to phase IB. With support from MUSC Health, phase I studies can be seamlessly implemented both in-patient and/or out-patient as needed. With a dedicated investigational drug pharmacy and a centralized clinical and translational research center, clinical and research services are available 24/7 and are supported by a dedicated team of phase I physicians.
For more information about the Phase I program, please contact the Clinical Trials Office.
As an NCI-Designated Cancer Center, investigators often develop or implement trials based on research conducted right here at Hollings Cancer Center. The Sponsor Investigator Support (SIS) unit assists principal investigators with the study development process including but not limited to the development of the protocol, budget, operations manual, vendor management, multi-site management and IND/IDE preparation and support. SIS services vary by study and SIS staff work with various pharmaceutical companies.
For more information about the SIS Unit, please contact Tricia Bentz.
For information regarding the Clinical Trials Office or any of the services listed, please contact Terri Matson.